Abstract Number: 4CPS-172

ATC code: 4. Historical research

POSACONAZOL THERAPEUTIC DRUG MONITORING IN A PAEDIATRIC TERTIARY HOSPITAL

A. Font, J. Arrojo, A. Comes, N. Mas, M. Sanchez, J. Vinent
Hospital Sant Joan de Déu, Pharmacy Department, Barcelona, Spain

BACKGROUND AND IMPORTANCE

➢Posaconazol is used for prophylaxis and treatment of IFD, although there is scarce data on its pharmacokinetics and optimal posology in children.

➢Posology

•**Oral suspension:** 4mg/kg (max 400 mg) tds

•**Tablets:** 6mg/kg (max 300 mg) od (bd on day 1)

OBJECTIVES

➢Determine the number of patients who achieved therapeutic plasma concentrations at steady state (ssCp) **(0.7µg/mL-3.75µg/mL)** with the dosing schedule of our institutional protocol.

➢Describe and analyse the pharmaceutical interventions necessary to achieve optimal ssCp and avoid toxicities or treatment failure.

MATERIAL AND METHODS

- Retrospective, observational, single-center study.
- 103 immunocompromised patients receiving prophylactic Posaconazol from April 2020 to September 2021.
-Variables collected: age, weight, formulation and trough ssCp.

RESULTS

➢Patient characteristics

AGE (median, CI)	WEIGHT (mean± SD)
9 years (2-23)	33,6kg (±18,3)

➢Pharmaceutical Form



➢ssCp after the first draw



➢Pharmaceutical interventions

356 pharmaceutical interventions were performed, 151 in patients taking oral suspension and 205 receiving tablets.



Patients receiving oral suspension



Patients receiving tablets

CONCLUSION AND RELEVANCE

➢Most patients achieved therapeutic ssCp after the first determination according to our scheme.

➢The need of dose adjustments was more frequent among the oral suspension group in order to achieve a correct ssCp, which is consistent with adult and pediatric population studies.

➢Importance of pharmacokinetics studies of posaconazol in paediatric population.